Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Jazz Pharmaceuticals plc Director's Dealing 2021

Mar 1, 2021

30751_dirs_2021-03-01_23021f36-68e0-451b-8bb6-a9fefb2ce7b5.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Jazz Pharmaceuticals plc (JAZZ)
CIK: 0001232524
Period of Report: 2021-02-25

Reporting Person: Larkin Finbar (SVP, Technical Operations)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2021-02-25 Ordinary Shares A 3950 $0.0 Acquired 18028 Direct

Footnotes

F1: These restricted stock units are granted pursuant to the Issuer's 2011 Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one ordinary share upon the vesting of the unit. These units vest in equal annual installments over four years measured from the vesting commencement date of March 5, 2021, with 1/4th vesting on the first anniversary of the vesting commencement date and the remainder vesting in equal annual installments over the subsequent three years.

F2: Includes 114 ordinary shares acquired under a Section 423 Employee Stock Purchase Plan on November 30, 2020.